Clinical-stage biotech
Appears in 1 story · Last updated Oct 31, 2026
Developer of zemprocitinib (LNK01001)
Many rheumatoid arthritis patients do not get enough relief from biologic drugs, the usual next step after methotrexate. Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib kept 91.8% of those patients at an ACR20 response through 76 weeks.
Updated Oct 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
